Streetbeat News

IVBXF

Innovent Biologics Inc

http://innoventbio.com

CEO

De-Chao Yu

Industry

Research and Development in Biotechnology

Open

5.25

Mkt cap

Volume

700

High

5.25

P/E Ratio

-44.14

52-wk high

6.40

Low

4.86

Div yield

N/A

52-wk low

3.83

The Claudin18.2-targeted therapy market is projected to grow due to positive results from current medications and an expanding pipeline. The market is characterized by global collaboration and competition, with significant contributions from both Western and Asian companies. This growth is expected to enhance cancer treatment options, particularly for difficult-to-treat cancers.

Portfolio Pulse from

November 22, 2024 | 10:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.